Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA. The post Could buying this gene-editing penny stock at $1 make me ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their ...

John Greene, a director at $CRSP, bought 7,000 shares of the company on 02-26-2025 for an estimated $313,947. This trade was reported by Quiver Quantitative using ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...